Participants 645 952 7
2006 to 2009, ARIES enrolled patients with locally advanced or metastatic NSCLC who were eligible for bevacizumab, excluding those with predominantly squamous histology. Patients were required to provide informed consent and to have initiated bevacizumab with chemotherapy within 4 months before enrollment.
Participants 1167 1202 4
1967 patients with first-line NSCLC
Participants 1274 1367 5
Median age was 65 years (range, 31-93), and 252 patients (12.8%) identified as never smokers.
